Noveris Health Sciences Inc.

For the year ended December 31, 2020, net loss attributable to common stockholders was $26.9 million, up from $21.5 million in 2019. Basic and diluted loss per share attributable to common stockholders was $0.24, versus $0.96 in 2019. Cash and cash equivalents were $2.2 million at year-end 2020. Subsequent to year-end, Mydecine said it raised approximately $30 million in the first month of 2021, and management said it believes it has sufficient liquidity to execute planned 2021 activities and meet commitments to date.

Josh Bartch framed the year as foundational, emphasizing Mydecine’s goal of building a vertically integrated psychedelic therapeutics company across R&D, IP, and telehealth. He pointed to the Mindleap and NeuroPharm acquisitions, the API partnership, and university-sponsored studies as evidence of a broad platform. His tone was optimistic and forward-looking, focused on upcoming milestones such as Phase 2a data, Mindleap version 2, and the company’s push toward broader market visibility.

Dean Ditto focused on the reported 2020 financials and balance sheet. He said net loss attributable to common stockholders was $26.9 million, or $0.24 per share, versus a $21.5 million loss and $0.96 per share in 2019. He also noted year-end cash of $2.2 million and said the company raised approximately $30 million in early 2021, which he said should provide sufficient liquidity for 2021 planned activities and commitments.

There was no substantive analyst Q&A in the transcript. The main investor-facing themes were management’s explanation of the company’s acquisitions, its NASDAQ listing application, and the expected timing of Mindleap version 2 and Phase 2a data. Management also said it had taken steps such as adding an independent board, engaging MNP and US counsel, and spinning out cannabis assets as prerequisites for listing.